1-3 of 3
Milan Kostal
Close
Sort by
Journal Articles

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Nichola Cooper, A.J. Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F Ypma, Vickie McDonald, Charles Percy, Milan Košťál, Isaac Goncalves, Lachezar H. Bogdanov, Terry B Gernsheimer, Remco Diab, Mengjie Yao, Ahmed Daak, David J Kuter
Journal: Blood
Blood (2023) 142 (Supplement 1): 685.
https://doi.org/10.1182/blood-2023-177808
Published: 2023
Journal Articles

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

David J. Kuter, Nikolay Tzvetkov, Merlin Efraim, Zane Kaplan, Jiří Mayer, Philip Choi, A.J. Gerard Jansen, Vickie McDonald, Ross Baker, Robert J. Bird, Mamta Garg, Jaromir Gumulec, Milan Kostal, Terry Gernsheimer, Waleed Ghanima, Olga Bandman, Puneet Arora, Regan Burns, Mengjie Yao, Ahmed Daak, Timothee Sourdille, Fareha Iqbal, Dolca Thomas, Ann Neale, Nichola Cooper
Journal: Blood
Blood (2021) 138 (Supplement 1): 14.
https://doi.org/10.1182/blood-2021-145128
Published: 2021
Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 87.
https://doi.org/10.1182/blood-2019-122336
Published: 2019